These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Sotorasib Shows Intracranial Activity in Patients with Koster KL; Appenzeller C; Lauber A; Früh M; Schmid S Case Rep Oncol; 2022; 15(2):720-725. PubMed ID: 36157699 [TBL] [Abstract][Full Text] [Related]
25. Activity of sotorasib against brain metastases from NSCLC harboring Inno A; Marchetti F; Valerio M; Giaj Levra N; Alongi F; Foti G; Gori S Drug Target Insights; 2023; 17():90-91. PubMed ID: 37408855 [TBL] [Abstract][Full Text] [Related]
26. Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program. Passiglia F; Lucia Reale M; Lo Russo G; Pasello G; Minuti G; Bulotta A; Galetta D; Pelizzari G; Sini C; Bria E; Roca E; Pilotto S; Genova C; Metro G; Citarella F; Chiari R; Cortinovis D; Delmonte A; Russo A; Tiseo M; Cerea G; Carta A; Scotti V; Vavalà T; Brambilla M; Buffoni L; Buosi R; Catania C; Gori S; Grisanti S; Agustoni F; Garbo E; Malapelle U; Novello S Lung Cancer; 2024 Jan; 187():107444. PubMed ID: 38157806 [TBL] [Abstract][Full Text] [Related]
27. Sotorasib as first-line therapy in patients with advanced non-small cell lung cancer with KRAS gene mutations combined with brain metastases: a case report. Jia X; Liu M; Cheng Z AME Case Rep; 2024; 8():48. PubMed ID: 38711902 [TBL] [Abstract][Full Text] [Related]
29. Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review. Santarpia M; Ciappina G; Spagnolo CC; Squeri A; Passalacqua MI; Aguilar A; Gonzalez-Cao M; Giovannetti E; Silvestris N; Rosell R Transl Lung Cancer Res; 2023 Feb; 12(2):346-368. PubMed ID: 36895930 [TBL] [Abstract][Full Text] [Related]
30. Sotorasib for previously treated colorectal cancers with KRAS Fakih MG; Kopetz S; Kuboki Y; Kim TW; Munster PN; Krauss JC; Falchook GS; Han SW; Heinemann V; Muro K; Strickler JH; Hong DS; Denlinger CS; Girotto G; Lee MA; Henary H; Tran Q; Park JK; Ngarmchamnanrith G; Prenen H; Price TJ Lancet Oncol; 2022 Jan; 23(1):115-124. PubMed ID: 34919824 [TBL] [Abstract][Full Text] [Related]
31. The path to the clinic: a comprehensive review on direct KRAS Kwan AK; Piazza GA; Keeton AB; Leite CA J Exp Clin Cancer Res; 2022 Jan; 41(1):27. PubMed ID: 35045886 [TBL] [Abstract][Full Text] [Related]
32. Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC. Brazel D; Nagasaka M Target Oncol; 2024 May; 19(3):297-301. PubMed ID: 38739329 [TBL] [Abstract][Full Text] [Related]
33. Pharmacophoric analogs of sotorasib-entrapped KRAS G12C in its inactive GDP-bound conformation: covalent docking and molecular dynamics investigations. Oyedele AK; Ogunlana AT; Boyenle ID; Ibrahim NO; Gbadebo IO; Owolabi NA; Ayoola AM; Francis AC; Eyinade OH; Adelusi TI Mol Divers; 2023 Aug; 27(4):1795-1807. PubMed ID: 36271195 [TBL] [Abstract][Full Text] [Related]
34. Remarkable Intracranial Response to Sotorasib in a Patient With Yeh J; Marks JA; Alzeer AH; Sloan EA; Varghese R; Paudel N; Reuss JE; Bergquist PJ; Liu SV; Kim C JTO Clin Res Rep; 2022 Dec; 3(12):100428. PubMed ID: 36471683 [TBL] [Abstract][Full Text] [Related]
35. Nonclinical Safety Profile of Sotorasib, a KRAS Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of ULK1/2 and KRAS Ghazi PC; O'Toole KT; Srinivas Boggaram S; Scherzer MT; Silvis MR; Zhang Y; Bogdan M; Smith BD; Lozano G; Flynn DL; Snyder EL; Kinsey CG; McMahon M bioRxiv; 2024 Jun; ():. PubMed ID: 38370808 [TBL] [Abstract][Full Text] [Related]
37. Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy. Kirschner T; Müller MP; Rauh D J Med Chem; 2024 Apr; 67(8):6044-6051. PubMed ID: 38621359 [TBL] [Abstract][Full Text] [Related]
38. Targeting Ji J; Wang C; Fakih M Onco Targets Ther; 2022; 15():747-756. PubMed ID: 35837349 [TBL] [Abstract][Full Text] [Related]
39. First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a De SK Curr Med Chem; 2024; 31(3):266-272. PubMed ID: 37005530 [TBL] [Abstract][Full Text] [Related]
40. Returning from the afterlife? Sotorasib treatment for advanced KRAS mutant lung cancer: A case report. Wang MX; Zhu P; Shi Y; Sun QM; Dong WH World J Clin Cases; 2024 Sep; 12(25):5805-5813. PubMed ID: 39247747 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]